ID AADAT_HUMAN Reviewed; 425 AA. AC Q8N5Z0; B3KP84; Q9UL02; DT 13-APR-2004, integrated into UniProtKB/Swiss-Prot. DT 13-APR-2004, sequence version 2. DT 09-APR-2025, entry version 182. DE RecName: Full=Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial {ECO:0000305}; DE Short=KAT/AadAT; DE AltName: Full=2-aminoadipate aminotransferase; DE AltName: Full=2-aminoadipate transaminase; DE EC=2.6.1.39 {ECO:0000269|PubMed:12126930, ECO:0000269|PubMed:18620547}; DE AltName: Full=Alpha-aminoadipate aminotransferase; DE Short=AadAT; DE AltName: Full=Glycine transaminase AADAT {ECO:0000305}; DE EC=2.6.1.4 {ECO:0000269|PubMed:18620547}; DE AltName: Full=Kynurenine aminotransferase II; DE AltName: Full=Kynurenine--glyoxylate transaminase AADAT {ECO:0000305}; DE EC=2.6.1.63 {ECO:0000269|PubMed:18620547}; DE AltName: Full=Kynurenine--oxoglutarate aminotransferase II; DE AltName: Full=Kynurenine--oxoglutarate transaminase 2; DE EC=2.6.1.7 {ECO:0000269|PubMed:18056995, ECO:0000269|PubMed:18620547}; DE AltName: Full=Kynurenine--oxoglutarate transaminase II; DE AltName: Full=Methionine--glyoxylate transaminase AADAT {ECO:0000305}; DE EC=2.6.1.73 {ECO:0000269|PubMed:18620547}; DE Flags: Precursor; GN Name=AADAT {ECO:0000312|HGNC:HGNC:17929}; GN Synonyms=KAT2 {ECO:0000312|HGNC:HGNC:17929}, GN KYAT2 {ECO:0000312|HGNC:HGNC:17929}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Brain; RA Gatti S., Breton J., Mostardini M., Mosca M., Tarroni P., Schwarcz R., RA Speciale C., Okuno E., Toma S., Benatti L.; RT "Cloning of human L-kynurenine/alpha-aminoadipate aminotransferase cDNA RT from brain tissue."; RL Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, AND RP COFACTOR. RX PubMed=12126930; DOI=10.1016/s1096-7192(02)00037-9; RA Goh D.L.M., Patel A., Thomas G.H., Salomons G.S., Schor D.S.M., Jakobs C., RA Geraghty M.T.; RT "Characterization of the human gene encoding alpha-aminoadipate RT aminotransferase (AADAT)."; RL Mol. Genet. Metab. 76:172-180(2002). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [6] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH 2-OXOGLUTARATE, RP CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY REGULATION, RP SUBUNIT, AND FUNCTION. RX PubMed=18620547; DOI=10.1042/bsr20080085; RA Han Q., Cai T., Tagle D.A., Robinson H., Li J.; RT "Substrate specificity and structure of human aminoadipate RT aminotransferase/kynurenine aminotransferase II."; RL Biosci. Rep. 28:205-215(2008). RN [7] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL PHOSPHATE RP AND KYRUNENINE, CATALYTIC ACTIVITY, FUNCTION, COFACTOR, AND SUBUNIT. RX PubMed=18056995; DOI=10.1074/jbc.m708358200; RA Han Q., Robinson H., Li J.; RT "Crystal structure of human kynurenine aminotransferase II."; RL J. Biol. Chem. 283:3567-3573(2008). RN [8] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH PYRIDOXAL PHOSPHATE, RP SUBUNIT, AND COFACTOR. RX PubMed=18056996; DOI=10.1074/jbc.m707925200; RA Rossi F., Garavaglia S., Montalbano V., Walsh M.A., Rizzi M.; RT "Crystal structure of human kynurenine aminotransferase II, a drug target RT for the treatment of schizophrenia."; RL J. Biol. Chem. 283:3559-3566(2008). CC -!- FUNCTION: Transaminase with broad substrate specificity. Has CC transaminase activity towards aminoadipate, kynurenine, methionine and CC glutamate. Shows activity also towards tryptophan, aspartate and CC hydroxykynurenine. Accepts a variety of oxo-acids as amino-group CC acceptors, with a preference for 2-oxoglutarate, 2-oxocaproic acid, CC phenylpyruvate and alpha-oxo-gamma-methiol butyric acid. Can also use CC glyoxylate as amino-group acceptor (in vitro). CC {ECO:0000269|PubMed:12126930, ECO:0000269|PubMed:18056995, CC ECO:0000269|PubMed:18620547}. CC -!- CATALYTIC ACTIVITY: CC Reaction=glycine + 2-oxoglutarate = glyoxylate + L-glutamate; CC Xref=Rhea:RHEA:14089, ChEBI:CHEBI:16810, ChEBI:CHEBI:29985, CC ChEBI:CHEBI:36655, ChEBI:CHEBI:57305; EC=2.6.1.4; CC Evidence={ECO:0000269|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-kynurenine + 2-oxoglutarate = kynurenate + L-glutamate + CC H2O; Xref=Rhea:RHEA:65560, ChEBI:CHEBI:15377, ChEBI:CHEBI:16810, CC ChEBI:CHEBI:29985, ChEBI:CHEBI:57959, ChEBI:CHEBI:58454; EC=2.6.1.7; CC Evidence={ECO:0000269|PubMed:18056995, ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:65561; CC Evidence={ECO:0000305|PubMed:18056995, ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-kynurenine + glyoxylate = kynurenate + glycine + H2O; CC Xref=Rhea:RHEA:65896, ChEBI:CHEBI:15377, ChEBI:CHEBI:36655, CC ChEBI:CHEBI:57305, ChEBI:CHEBI:57959, ChEBI:CHEBI:58454; EC=2.6.1.63; CC Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:65897; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=3-hydroxy-L-kynurenine + glyoxylate = xanthurenate + glycine + CC H2O; Xref=Rhea:RHEA:65900, ChEBI:CHEBI:15377, ChEBI:CHEBI:36655, CC ChEBI:CHEBI:57305, ChEBI:CHEBI:58125, ChEBI:CHEBI:71201; EC=2.6.1.63; CC Evidence={ECO:0000269|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2-oxohexanoate + L-kynurenine = L-2-aminohexanoate + CC kynurenate + H2O; Xref=Rhea:RHEA:66060, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:35177, ChEBI:CHEBI:57959, ChEBI:CHEBI:58454, CC ChEBI:CHEBI:58455; Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66061; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=3-phenylpyruvate + L-kynurenine = kynurenate + L-phenylalanine CC + H2O; Xref=Rhea:RHEA:66092, ChEBI:CHEBI:15377, ChEBI:CHEBI:18005, CC ChEBI:CHEBI:57959, ChEBI:CHEBI:58095, ChEBI:CHEBI:58454; CC Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66093; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=4-methylsulfanyl-2-oxobutanoate + L-kynurenine = kynurenate + CC L-methionine + H2O; Xref=Rhea:RHEA:69096, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:16723, ChEBI:CHEBI:57844, ChEBI:CHEBI:57959, CC ChEBI:CHEBI:58454; Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:69097; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2-oxo-3-sulfanylpropanoate + L-kynurenine = kynurenate + L- CC cysteine + H2O; Xref=Rhea:RHEA:69104, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:35235, ChEBI:CHEBI:57678, ChEBI:CHEBI:57959, CC ChEBI:CHEBI:58454; Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:69105; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=indole-3-pyruvate + L-kynurenine = kynurenate + L-tryptophan + CC H2O; Xref=Rhea:RHEA:66052, ChEBI:CHEBI:15377, ChEBI:CHEBI:17640, CC ChEBI:CHEBI:57912, ChEBI:CHEBI:57959, ChEBI:CHEBI:58454; CC Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66053; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2-oxopentanoate + L-kynurenine = L-2-aminopentanoate + CC kynurenate + H2O; Xref=Rhea:RHEA:66076, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:28644, ChEBI:CHEBI:57959, ChEBI:CHEBI:58441, CC ChEBI:CHEBI:58454; Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66077; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=4-methyl-2-oxopentanoate + L-kynurenine = kynurenate + L- CC leucine + H2O; Xref=Rhea:RHEA:66068, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:17865, ChEBI:CHEBI:57427, ChEBI:CHEBI:57959, CC ChEBI:CHEBI:58454; Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66069; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-2-aminoadipate + 2-oxoglutarate = 2-oxoadipate + L- CC glutamate; Xref=Rhea:RHEA:12601, ChEBI:CHEBI:16810, CC ChEBI:CHEBI:29985, ChEBI:CHEBI:57499, ChEBI:CHEBI:58672; EC=2.6.1.39; CC Evidence={ECO:0000269|PubMed:12126930, ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12602; CC Evidence={ECO:0000305|PubMed:12126930}; CC -!- CATALYTIC ACTIVITY: CC Reaction=glyoxylate + L-methionine = 4-methylsulfanyl-2-oxobutanoate + CC glycine; Xref=Rhea:RHEA:22884, ChEBI:CHEBI:16723, ChEBI:CHEBI:36655, CC ChEBI:CHEBI:57305, ChEBI:CHEBI:57844; EC=2.6.1.73; CC Evidence={ECO:0000269|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-2-aminoadipate + glyoxylate = 2-oxoadipate + glycine; CC Xref=Rhea:RHEA:69112, ChEBI:CHEBI:36655, ChEBI:CHEBI:57305, CC ChEBI:CHEBI:57499, ChEBI:CHEBI:58672; CC Evidence={ECO:0000269|PubMed:18620547}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:69113; CC Evidence={ECO:0000305|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosine + glyoxylate = 3-(4-hydroxyphenyl)pyruvate + CC glycine; Xref=Rhea:RHEA:69116, ChEBI:CHEBI:36242, ChEBI:CHEBI:36655, CC ChEBI:CHEBI:57305, ChEBI:CHEBI:58315; CC Evidence={ECO:0000269|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=glyoxylate + L-phenylalanine = 3-phenylpyruvate + glycine; CC Xref=Rhea:RHEA:69120, ChEBI:CHEBI:18005, ChEBI:CHEBI:36655, CC ChEBI:CHEBI:57305, ChEBI:CHEBI:58095; CC Evidence={ECO:0000269|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tryptophan + glyoxylate = indole-3-pyruvate + glycine; CC Xref=Rhea:RHEA:69124, ChEBI:CHEBI:17640, ChEBI:CHEBI:36655, CC ChEBI:CHEBI:57305, ChEBI:CHEBI:57912; CC Evidence={ECO:0000269|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-leucine + glyoxylate = 4-methyl-2-oxopentanoate + glycine; CC Xref=Rhea:RHEA:69128, ChEBI:CHEBI:17865, ChEBI:CHEBI:36655, CC ChEBI:CHEBI:57305, ChEBI:CHEBI:57427; CC Evidence={ECO:0000269|PubMed:18620547}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2-oxobutanoate + L-kynurenine = (2S)-2-aminobutanoate + CC kynurenate + H2O; Xref=Rhea:RHEA:66044, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:16763, ChEBI:CHEBI:57959, ChEBI:CHEBI:58454, CC ChEBI:CHEBI:74359; Evidence={ECO:0000250|UniProtKB:Q64602}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:66045; CC Evidence={ECO:0000250|UniProtKB:Q64602}; CC -!- CATALYTIC ACTIVITY: CC Reaction=2-oxoadipate + L-kynurenine = L-2-aminoadipate + kynurenate + CC H2O; Xref=Rhea:RHEA:70047, ChEBI:CHEBI:15377, ChEBI:CHEBI:57499, CC ChEBI:CHEBI:57959, ChEBI:CHEBI:58454, ChEBI:CHEBI:58672; CC Evidence={ECO:0000250|UniProtKB:Q64602}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70048; CC Evidence={ECO:0000250|UniProtKB:Q64602}; CC -!- COFACTOR: CC Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326; CC Evidence={ECO:0000269|PubMed:12126930, ECO:0000269|PubMed:18056995, CC ECO:0000269|PubMed:18056996}; CC -!- ACTIVITY REGULATION: Kynurenine transaminase activity is competitively CC inhibited by aminoadipate, asparagine, glutamate, histidine, cysteine, CC lysine, 3-hydroxy-kynurenine and phenylalanine. CC {ECO:0000269|PubMed:18620547}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=0.9 mM for aminoadipate {ECO:0000269|PubMed:18620547}; CC KM=4.7 mM for kynurenine {ECO:0000269|PubMed:18620547}; CC KM=1.7 mM for methionine {ECO:0000269|PubMed:18620547}; CC KM=1.6 mM for glutamate {ECO:0000269|PubMed:18620547}; CC KM=1.8 mM for tyrosine {ECO:0000269|PubMed:18620547}; CC KM=1.2 mM for 2-oxoglutarate {ECO:0000269|PubMed:18620547}; CC KM=1.5 mM for 2-oxocaproic acid {ECO:0000269|PubMed:18620547}; CC KM=1.8 mM for phenylpyruvate {ECO:0000269|PubMed:18620547}; CC KM=1.4 mM for ino-3-pyruvate {ECO:0000269|PubMed:18620547}; CC pH dependence: CC Optimum pH is 7-9. {ECO:0000269|PubMed:18620547}; CC Temperature dependence: CC Optimum temperature is 50 degrees Celsius. CC {ECO:0000269|PubMed:18620547}; CC -!- PATHWAY: Amino-acid degradation; L-lysine degradation via saccharopine CC pathway; glutaryl-CoA from L-lysine: step 4/6. CC -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:18056995, CC ECO:0000269|PubMed:18056996, ECO:0000269|PubMed:18620547}. CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q8N5Z0-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8N5Z0-2; Sequence=VSP_009874; CC -!- TISSUE SPECIFICITY: Higher expression in the liver. Also found in CC heart, brain, kidney, pancreas, prostate, testis and ovary. CC -!- MISCELLANEOUS: [Isoform 1]: May be due to a competing donor splice CC site. CC -!- SIMILARITY: Belongs to the class-I pyridoxal-phosphate-dependent CC aminotransferase family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF097994; AAF04623.1; -; mRNA. DR EMBL; AF481738; AAM09683.1; -; mRNA. DR EMBL; AK055952; BAG51596.1; -; mRNA. DR EMBL; BC031068; AAH31068.1; -; mRNA. DR CCDS; CCDS3814.1; -. [Q8N5Z0-1] DR CCDS; CCDS75209.1; -. [Q8N5Z0-2] DR RefSeq; NP_001273611.1; NM_001286682.2. [Q8N5Z0-2] DR RefSeq; NP_001273612.1; NM_001286683.1. [Q8N5Z0-1] DR RefSeq; NP_057312.1; NM_016228.4. [Q8N5Z0-1] DR RefSeq; NP_872603.1; NM_182662.2. [Q8N5Z0-1] DR RefSeq; XP_024309845.1; XM_024454077.2. [Q8N5Z0-1] DR RefSeq; XP_047271719.1; XM_047415763.1. [Q8N5Z0-1] DR RefSeq; XP_054206124.1; XM_054350149.1. [Q8N5Z0-1] DR RefSeq; XP_054206125.1; XM_054350150.1. [Q8N5Z0-1] DR PDB; 2QLR; X-ray; 2.30 A; A/B/C/D=1-425. DR PDB; 2R2N; X-ray; 1.95 A; A/B/C/D=1-425. DR PDB; 2VGZ; X-ray; 2.30 A; A/B=2-425. DR PDB; 2XH1; X-ray; 2.10 A; A/B=1-425. DR PDB; 3DC1; X-ray; 2.50 A; A/B/C/D=1-425. DR PDB; 3UE8; X-ray; 3.22 A; A/B=1-425. DR PDB; 4GDY; X-ray; 2.89 A; A/B=1-425. DR PDB; 4GE4; X-ray; 2.41 A; A/B=1-425. DR PDB; 4GE7; X-ray; 2.10 A; A/B=1-425. DR PDB; 4GE9; X-ray; 2.43 A; A/B/C/D=1-425. DR PDB; 4GEB; X-ray; 2.15 A; A/B=1-425. DR PDB; 5EFS; X-ray; 1.83 A; A=1-425. DR PDB; 5EUN; X-ray; 1.82 A; A=1-425. DR PDB; 5TF5; X-ray; 1.81 A; A/B=1-425. DR PDB; 6D0A; X-ray; 1.47 A; A=1-425. DR PDB; 6T8P; X-ray; 2.02 A; A/B=1-425. DR PDB; 6T8Q; X-ray; 2.51 A; A=1-425. DR PDBsum; 2QLR; -. DR PDBsum; 2R2N; -. DR PDBsum; 2VGZ; -. DR PDBsum; 2XH1; -. DR PDBsum; 3DC1; -. DR PDBsum; 3UE8; -. DR PDBsum; 4GDY; -. DR PDBsum; 4GE4; -. DR PDBsum; 4GE7; -. DR PDBsum; 4GE9; -. DR PDBsum; 4GEB; -. DR PDBsum; 5EFS; -. DR PDBsum; 5EUN; -. DR PDBsum; 5TF5; -. DR PDBsum; 6D0A; -. DR PDBsum; 6T8P; -. DR PDBsum; 6T8Q; -. DR AlphaFoldDB; Q8N5Z0; -. DR SMR; Q8N5Z0; -. DR BioGRID; 119346; 22. DR IntAct; Q8N5Z0; 1. DR STRING; 9606.ENSP00000423190; -. DR BindingDB; Q8N5Z0; -. DR ChEMBL; CHEMBL2046259; -. DR DrugBank; DB00142; Glutamic acid. DR DrugBank; DB00114; Pyridoxal phosphate. DR GlyGen; Q8N5Z0; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q8N5Z0; -. DR PhosphoSitePlus; Q8N5Z0; -. DR SwissPalm; Q8N5Z0; -. DR BioMuta; AADAT; -. DR DMDM; 46395904; -. DR jPOST; Q8N5Z0; -. DR MassIVE; Q8N5Z0; -. DR PaxDb; 9606-ENSP00000423190; -. DR PeptideAtlas; Q8N5Z0; -. DR ProteomicsDB; 72114; -. [Q8N5Z0-1] DR ProteomicsDB; 72115; -. [Q8N5Z0-2] DR Pumba; Q8N5Z0; -. DR Antibodypedia; 17143; 355 antibodies from 35 providers. DR DNASU; 51166; -. DR Ensembl; ENST00000337664.9; ENSP00000336808.4; ENSG00000109576.14. [Q8N5Z0-1] DR Ensembl; ENST00000353187.6; ENSP00000226840.4; ENSG00000109576.14. [Q8N5Z0-1] DR Ensembl; ENST00000509167.5; ENSP00000423190.1; ENSG00000109576.14. [Q8N5Z0-2] DR Ensembl; ENST00000515480.5; ENSP00000423341.1; ENSG00000109576.14. [Q8N5Z0-1] DR GeneID; 51166; -. DR KEGG; hsa:51166; -. DR MANE-Select; ENST00000337664.9; ENSP00000336808.4; NM_016228.4; NP_057312.1. DR UCSC; uc003isr.4; human. [Q8N5Z0-1] DR AGR; HGNC:17929; -. DR CTD; 51166; -. DR DisGeNET; 51166; -. DR GeneCards; AADAT; -. DR HGNC; HGNC:17929; AADAT. DR HPA; ENSG00000109576; Tissue enhanced (liver). DR MIM; 611754; gene. DR neXtProt; NX_Q8N5Z0; -. DR OpenTargets; ENSG00000109576; -. DR PharmGKB; PA24364; -. DR VEuPathDB; HostDB:ENSG00000109576; -. DR eggNOG; KOG0634; Eukaryota. DR GeneTree; ENSGT00390000004594; -. DR HOGENOM; CLU_017584_0_6_1; -. DR InParanoid; Q8N5Z0; -. DR OMA; FMPGEPF; -. DR OrthoDB; 691673at2759; -. DR PhylomeDB; Q8N5Z0; -. DR TreeFam; TF328598; -. DR BioCyc; MetaCyc:HS03239-MONOMER; -. DR BRENDA; 2.6.1.39; 2681. DR BRENDA; 2.6.1.7; 2681. DR PathwayCommons; Q8N5Z0; -. DR Reactome; R-HSA-71064; Lysine catabolism. DR Reactome; R-HSA-71240; Tryptophan catabolism. DR SABIO-RK; Q8N5Z0; -. DR SignaLink; Q8N5Z0; -. DR UniPathway; UPA00868; UER00838. DR BioGRID-ORCS; 51166; 24 hits in 1155 CRISPR screens. DR ChiTaRS; AADAT; human. DR EvolutionaryTrace; Q8N5Z0; -. DR GenomeRNAi; 51166; -. DR Pharos; Q8N5Z0; Tchem. DR PRO; PR:Q8N5Z0; -. DR Proteomes; UP000005640; Chromosome 4. DR RNAct; Q8N5Z0; protein. DR Bgee; ENSG00000109576; Expressed in right lobe of liver and 143 other cell types or tissues. DR ExpressionAtlas; Q8N5Z0; baseline and differential. DR GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; HTP:FlyBase. DR GO; GO:0047536; F:2-aminoadipate transaminase activity; IDA:UniProtKB. DR GO; GO:0047958; F:glycine:2-oxoglutarate aminotransferase activity; IDA:UniProtKB. DR GO; GO:0047315; F:kynurenine-glyoxylate transaminase activity; IDA:UniProtKB. DR GO; GO:0016212; F:kynurenine-oxoglutarate transaminase activity; IDA:UniProtKB. DR GO; GO:0050094; F:methionine-glyoxylate transaminase activity; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB. DR GO; GO:0030170; F:pyridoxal phosphate binding; IEA:InterPro. DR GO; GO:0006103; P:2-oxoglutarate metabolic process; IDA:UniProtKB. DR GO; GO:1901605; P:alpha-amino acid metabolic process; IBA:GO_Central. DR GO; GO:0009058; P:biosynthetic process; IEA:InterPro. DR GO; GO:0006536; P:glutamate metabolic process; IDA:UniProtKB. DR GO; GO:0070189; P:kynurenine metabolic process; IDA:UniProtKB. DR GO; GO:0033512; P:L-lysine catabolic process to acetyl-CoA via saccharopine; IEA:UniProtKB-UniPathway. DR CDD; cd00609; AAT_like; 1. DR FunFam; 3.40.640.10:FF:000071; Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial; 1. DR FunFam; 3.90.1150.10:FF:000166; Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial; 1. DR Gene3D; 3.40.640.10; Type I PLP-dependent aspartate aminotransferase-like (Major domain); 1. DR InterPro; IPR004839; Aminotransferase_I/II_large. DR InterPro; IPR050859; Class-I_PLP-dep_aminotransf. DR InterPro; IPR015424; PyrdxlP-dep_Trfase. DR InterPro; IPR015421; PyrdxlP-dep_Trfase_major. DR PANTHER; PTHR42790; AMINOTRANSFERASE; 1. DR PANTHER; PTHR42790:SF19; KYNURENINE_ALPHA-AMINOADIPATE AMINOTRANSFERASE, MITOCHONDRIAL; 1. DR Pfam; PF00155; Aminotran_1_2; 1. DR SUPFAM; SSF53383; PLP-dependent transferases; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Aminotransferase; KW Mitochondrion; Proteomics identification; Pyridoxal phosphate; KW Reference proteome; Transferase; Transit peptide. FT TRANSIT 1..29 FT /note="Mitochondrion" FT /evidence="ECO:0000255" FT CHAIN 30..425 FT /note="Kynurenine/alpha-aminoadipate aminotransferase, FT mitochondrial" FT /id="PRO_0000020602" FT REGION 181..208 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 198..208 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 20 FT /ligand="substrate" FT BINDING 74 FT /ligand="substrate" FT BINDING 142 FT /ligand="substrate" FT BINDING 202 FT /ligand="substrate" FT BINDING 399 FT /ligand="substrate" FT MOD_RES 69 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT MOD_RES 179 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT MOD_RES 263 FT /note="N6-(pyridoxal phosphate)lysine; alternate" FT MOD_RES 263 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT MOD_RES 263 FT /note="N6-succinyllysine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT MOD_RES 339 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT MOD_RES 339 FT /note="N6-succinyllysine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT MOD_RES 367 FT /note="N6-acetyllysine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT MOD_RES 367 FT /note="N6-succinyllysine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT MOD_RES 422 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q9WVM8" FT VAR_SEQ 23 FT /note="T -> SEKRA (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_009874" FT VARIANT 243 FT /note="V -> I (in dbSNP:rs56350236)" FT /id="VAR_061005" FT CONFLICT 103 FT /note="P -> Q (in Ref. 4; AAH31068)" FT /evidence="ECO:0000305" FT CONFLICT 380 FT /note="L -> S (in Ref. 3; BAG51596)" FT /evidence="ECO:0000305" FT HELIX 3..6 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 9..13 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 19..21 FT /evidence="ECO:0007829|PDB:2R2N" FT HELIX 23..27 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 43..45 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 51..53 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 56..58 FT /evidence="ECO:0007829|PDB:4GEB" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 65..71 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 81..95 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 98..101 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 104..106 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 109..116 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 117..128 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 134..137 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 143..149 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 150..152 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 155..158 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 168..175 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 180..184 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 186..188 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 193..196 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 202..204 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 210..223 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 226..230 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 232..235 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 239..241 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 247..249 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 251..253 FT /evidence="ECO:0007829|PDB:5TF5" FT STRAND 255..261 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 262..265 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 267..270 FT /evidence="ECO:0007829|PDB:4GE9" FT STRAND 272..277 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 278..289 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 290..292 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 293..295 FT /evidence="ECO:0007829|PDB:4GE7" FT HELIX 297..340 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 341..344 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 345..347 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 351..360 FT /evidence="ECO:0007829|PDB:6D0A" FT HELIX 368..371 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 372..378 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 381..383 FT /evidence="ECO:0007829|PDB:6T8P" FT HELIX 384..387 FT /evidence="ECO:0007829|PDB:6D0A" FT STRAND 388..390 FT /evidence="ECO:0007829|PDB:5TF5" FT STRAND 391..393 FT /evidence="ECO:0007829|PDB:3UE8" FT STRAND 397..401 FT /evidence="ECO:0007829|PDB:6D0A" FT TURN 402..404 FT /evidence="ECO:0007829|PDB:3UE8" FT HELIX 407..422 FT /evidence="ECO:0007829|PDB:6D0A" SQ SEQUENCE 425 AA; 47352 MW; 448CCAAB2173A7BA CRC64; MNYARFITAA SAARNPSPIR TMTDILSRGP KSMISLAGGL PNPNMFPFKT AVITVENGKT IQFGEEMMKR ALQYSPSAGI PELLSWLKQL QIKLHNPPTI HYPPSQGQMD LCVTSGSQQG LCKVFEMIIN PGDNVLLDEP AYSGTLQSLH PLGCNIINVA SDESGIVPDS LRDILSRWKP EDAKNPQKNT PKFLYTVPNG NNPTGNSLTS ERKKEIYELA RKYDFLIIED DPYYFLQFNK FRVPTFLSMD VDGRVIRADS FSKIISSGLR IGFLTGPKPL IERVILHIQV STLHPSTFNQ LMISQLLHEW GEEGFMAHVD RVIDFYSNQK DAILAAADKW LTGLAEWHVP AAGMFLWIKV KGINDVKELI EEKAVKMGVL MLPGNAFYVD SSAPSPYLRA SFSSASPEQM DVAFQVLAQL IKESL //